2019 Mar – 2024 Feb | $11.4M

Assessing safety, efficacy and transmission blocking properties of the new anti-malarial KAF156 combined with a new formulation of lumefantrine in children and adults with uncomplicated Plasmodium sp. malaria in West and Central Africa (WANECAM II) European & Developing Countries Clinical Trials Partnership (EDCTP), University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali | Abdoulaye Djimde | Gabon, Burkina Faso, Mali, Niger

Similar Posts

  • PYRAPREG

    Malaria in pregnant is a public health problem in sub Saharan countries where 11 million pregnancies are exposed to malaria infection. Plasmodium falciparum in pregnant can cause adverse maternal health and poor birth outcomes. Artemisin-based Combination Therapy (ACT) used in treatment of uncomplicated Plasmodium falciparum malaria in pregnant women has the efficacy in Africa. The…

  • 2021 Jan – 2024 Jan

    Increasing the uptake of IPTp-SP through Seasonal Malaria Chemoprevention channel delivery (INTEGRATION study) R-Evolution Worldwide, University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali, Research Institute of Health Sciences (IRSS), Burkina Faso | Kassoum Kayentao | Burkina Faso, Mali

  • 2007 May – 2008 Jun

    Randomized Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Pichia Pastoris-Expressed P. Falciparum Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Versus Tetanus Toxoid, in Healthy Malian Adult in Bandiagara African Malaria Network Trust (AMANET), Tanzania, University of Bamako, Mali | Mahamadou A. Thera | Africa, Western, Mali

Leave a Reply

Your email address will not be published. Required fields are marked *